

Fatih Eren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1497839/publications.pdf>

Version: 2024-02-01

71
papers

1,588
citations

304368

22
h-index

329751

37
g-index

74
all docs

74
docs citations

74
times ranked

2895
citing authors

#	ARTICLE	IF	CITATIONS
1	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 936-942.	1.4	37
2	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. <i>Angiology</i> , 2020, 71, 83-84.	0.8	1
3	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 642-649.	0.8	24
4	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, 98-103.	0.8	33
5	Evaluation of the Association between Programmed Cell Death-1 Gene Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 617-622.	0.5	3
6	Letter: the use of Fibrosis-4 score in primary care and diabetology practices”Occam’s razor applied to advanced fibrosis screening. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1759-1760.	1.9	7
7	Hepatic fibrosis “ and not steatosis “ is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2019, 290, 222-223.	0.4	2
8	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. <i>Hormones</i> , 2019, 18, 463-475.	0.9	8
9	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 43-46.	0.8	43
10	Comments on “The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease”, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, 548-548.	0.4	0
11	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1601-1602.	0.8	0
12	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1101-1108.	0.2	34
13	Top government hands-on megaproject management: the case of Istanbul’s grand airport. <i>International Journal of Managing Projects in Business</i> , 2019, 12, 666-693.	1.3	22
14	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 441-447.	0.8	21
15	Association of ERAP1, IL23R and PTGER4 Polymorphisms with Radiographic Severity of Ankylosing Spondylitis. <i>Open Rheumatology Journal</i> , 2017, 11, 1-9.	0.1	10
16	Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. <i>Turkish Journal of Gastroenterology</i> , 2017, 28, 327-328.	0.4	6
17	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 667-671.	0.8	10
18	Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. <i>Genetics and Molecular Biology</i> , 2015, 38, 21-29.	0.6	23

#	ARTICLE	IF	CITATIONS
19	SHBG Gene Polymorphism (rs1799941) Associates with Metabolic Syndrome in Children and Adolescents. PLoS ONE, 2015, 10, e0116915.	1.1	8
20	A Systems Genetics Approach to Dyslipidemia in Children and Adolescents. OMICS A Journal of Integrative Biology, 2015, 19, 248-259.	1.0	5
21	Familial Mediterranean fever gene (MEFV) mutations and disease severity in systemic lupus erythematosus (SLE): implications for the role of the E148Q MEFV allele in inflammation. Lupus, 2015, 24, 705-711.	0.8	16
22	The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1 α and VEGF. International Journal of Pharmaceutics, 2015, 478, 147-154.	2.6	44
23	Bactericidal permeability increasing protein gene polymorphism is associated with inflammatory bowel diseases in the Turkish population. Saudi Journal of Gastroenterology, 2015, 21, 239.	0.5	5
24	No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. Turkish Journal of Gastroenterology, 2015, 25, 639-43.	0.4	6
25	A comparison of FibroMeter ® , c NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2014, 49, 1343-1348.	0.6	43
26	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 1292-1295.	0.8	7
27	Investigation of the Therapeutic Efficacy of Codelivery of psiRNA â€ “Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model. Journal of Pharmaceutical Sciences, 2014, 103, 785-795.	1.6	17
28	The Frequency and the Effects of 21-Hydroxylase Gene Defects in Congenital Adrenal Hyperplasia Patients. Annals of Human Genetics, 2014, 78, 399-409.	0.3	11
29	Iliac artery perforation and treatment during lumbar disc surgery by simple balloon tamponade. European Spine Journal, 2013, 22, 350-352.	1.0	13
30	Multi-Locus Candidate Gene Analyses of Lipid Levels in a Pediatric Turkish Cohort: Lessons Learned on <i>LPL</i> , <i>CETP</i> , <i>LIPC</i> , <i>ABCA1</i> , and <i>SHBG</i> . OMICS A Journal of Integrative Biology, 2013, 17, 636-645.	1.0	10
31	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2013, 45, 58-62.	0.4	21
32	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori, 2013, 99, 10-16.	0.6	10
33	Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology, 2013, 12, 915-925.	0.6	7
34	Sex hormone binding globulin gene polymorphisms and metabolic syndrome in postmenopausal Turkish women. Cardiology Journal, 2013, 20, 287-293.	0.5	8
35	Percutaneous antegrade transarterial treatment of traumatic radial arteriovenous fistula. Turk Kardiyoloji Dernegi Arsivi, 2013, 41, 238-240.	0.6	1
36	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta, 2012, 414, 154-157.	0.5	16

#	ARTICLE	IF	CITATIONS
37	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2012, 45, 655-658.	0.8	43
38	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1488-1493.	0.6	19
39	Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer<i>In Vivo</i>. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 40-48.	2.0	38
40	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 631-636.	0.6	39
41	Serum levels of omentin, chemerin and adiponin in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 91-97.	0.6	107
42	Effects of lecithin: Cholesterol acyltransferase genotypes, enzyme levels, and activity on high-density lipoprotein levels. <i>Journal of Clinical Lipidology</i> , 2011, 5, 152-158.	0.6	9
43	Association between bactericidal/permeability increasing protein (BPI) gene polymorphism (Lys216Glu) and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 14-18.	0.6	18
44	Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 402-406.	0.6	21
45	The Association Between Bactericidal Permeability Increasing Protein (BPI) Gene Polymorphism and Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn's Disease's Subphenotypes. <i>Gastroenterology</i> , 2011, 140, S-484-S-485.	0.6	0
46	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. <i>Clinica Chimica Acta</i> , 2011, 412, 2296-2299.	0.5	14
47	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2011, 217, 125-129.	0.4	53
48	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 544-549.	1.5	61
49	Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?" <i>Metabolism: Clinical and Experimental</i> , 2011, 60, e2.	1.5	1
50	Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 59-63.	1.0	18
51	The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease. <i>Heart and Vessels</i> , 2011, 26, 457-463.	0.5	12
52	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. <i>Obesity Surgery</i> , 2011, 21, 1316-1317.	1.1	0
53	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2011, 44, 955-958.	0.8	10
54	Serum zinc- α 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 93-7.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Two-year results of primary coronary intervention performed in a medium-scale primary percutaneous coronary intervention center by two cardiologists who are not formally trained in interventional cardiology. <i>Anatolian Journal of Cardiology</i> , 2011, 11, 656-7.	0.4	0
56	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Disease Markers</i> , 2011, 31, 205-210.	0.6	24
57	R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History. <i>Pathology and Oncology Research</i> , 2010, 16, 563-568.	0.9	11
58	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2010, 40, 887-892.	1.7	159
59	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 541-546.	0.6	38
60	Chitosan/Short Hairpin RNA Complexes for Vascular Endothelial Growth Factor Suppression Invasive Breast Carcinoma. <i>Oligonucleotides</i> , 2010, 20, 183-190.	2.7	20
61	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2010, 411, 2029-2032.	0.5	12
62	595 VEGF, BFGF & ENDOSTATIN DO NOT PREDICT PROGNOSIS IN HEPATOCELLULAR CARCINOMA PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S234-S235.	1.8	0
63	Epidemiology and Diagnosis of Hepatitis B in the Mediterranean Region and Elsewhere. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2010, , 239-260.	0.5	0
64	Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats. <i>Turkish Journal of Gastroenterology</i> , 2010, 21, 287-292.	0.4	5
65	The effects of pegylated interferon alpha 2b on bile-duct ligation induced liver fibrosis in rats. <i>Annals of Hepatology</i> , 2009, 8, 234-240.	0.6	6
66	Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis. <i>Archives of Medical Research</i> , 2009, 40, 294-298.	1.5	28
67	Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. <i>Journal of Pineal Research</i> , 2009, 46, 401-407.	3.4	46
68	Role of Ursodeoxycholic Acid in Prevention of Methotrexate-induced Liver Toxicity. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1071-1077.	1.1	99
69	Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. <i>Journal of Hepatology</i> , 2007, 47, 851-859.	1.8	37
70	The Effects of N-Acetylcysteine on Bile Duct Ligation-Induced Liver Fibrosis in Rats. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3348-3354.	1.1	39
71	Rosiglitazone Attenuates Liver Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3465-3472.	1.1	56